Want to see BDTX full AI Analyst Report?

Black Diamond Therapeutics (BDTX) Price & Analysis

1,660 Followers

BDTX Stock Chart & Stats

$2.24

-$0.08(-4.35%)

At close: Jul 24 4:00 PM EDT

$2.24

-$0.08(-4.35%)

Day’s Range― - ―

52-Week Range$1.60 - $4.94

Previous CloseN/A

Volume623.29K

Average Volume (3M)607.19K

Market Cap

$121.80M

Enterprise Value$12.59

Total Cash (Recent Filing)$110.51M

Total Debt (Recent Filing)$16.97M

Price to Earnings (P/E)―

Beta2.27

Next Earnings

Nov 09, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding57,453,747

10 Day Avg. Volume499,771

30 Day Avg. Volume607,189

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)1.23

Price to Sales (P/S)1.97

P/FCF Ratio4.67

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$10.33

Price Target Upside361.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.63

Revenue Forecast (FY)$7.14M

Bulls Say, Bears Say

Bulls Say

Mutation-centric Precision Oncology PlatformThe mutation-centric approach focuses research on genetically defined patient groups and previously difficult-to-target alterations. If successfully translated into approved therapies, this specialization could support differentiated products, targeted clinical development, and durable positioning in precision oncology.

Conservative LeverageLow leverage provides greater financial flexibility than a heavily debt-funded development model. With debt substantially below equity, the company has less interest and refinancing pressure, which can help preserve strategic options while it advances clinical programs and manages ongoing cash needs.

Encouraging Phase 2 Clinical DataPositive Phase 2 activity indicators strengthen the clinical rationale for silevertinib and may improve its prospects for further development in NSCLC. Durable progression-free survival, response activity, CNS benefit, and no new safety signals could support future partnering or commercialization efforts.

Bears Say

No Recurring Commercial RevenueThe absence of recurring TTM revenue means the company remains dependent on clinical progress, financing, or potential collaboration economics rather than an established commercial product base. This makes future operating performance highly dependent on successful development and eventual regulatory execution.

Ongoing Cash BurnNegative operating and free cash flow indicate that ongoing research and development require external financial support. Although burn improved from 2024, the return to negative TTM cash flow shows that funding needs remain structurally relevant and could constrain development pace or capital allocation.

Volatile Profitability And Weak ReturnsThe sharp shift from 2025 profitability to TTM losses demonstrates that earnings power is not yet stable or repeatable. Negative returns on equity also indicate capital consumption without current value creation, making sustained profitability dependent on future clinical and commercial success.

Black Diamond Therapeutics News

Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2

Raymond James analyst Sean McCutcheon maintains a “constructive view” around the market opportunity and unmet need in first-line...

1M ago

BDTX

Black Diamond Therapeutics setup ‘attractive,’ says Jefferies

Jefferies analyst Maury Raycroft views the Q4 setup for Black Diamond Therapeutics (BDTX) as “attractive” as it sees...

1M ago

BDTX

Black Diamond Therapeutics: Buy Rating Reiterated with Unchanged $11 Price Target on Clinical Catalysts and Strong Cash Runway

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BDTX stock, giving a Buy rating yesterday....

1M ago

BDTX

Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)

“Silevertinib continued to demonstrate robust clinical activity and durable responses in frontline patients with non-classical EGFR-mutant NSCLC, as...

1M ago

BDTX

Black Diamond Shareholders Approve Directors and Annual Say-on-Pay

The latest announcement is out from Black Diamond Therapeutics ( ($BDTX) ). On June 26, 2026, Black Diamond...

2M ago

BDTX

Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data

Black Diamond Therapeutics ( ($BDTX) ) has issued an update. On May 21, 2026, Black Diamond Therapeutics reported...

4M ago

BDTX

Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028

TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating on...

4M ago

BDTX

Black Diamond price target raised to $11 from $10 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $11 from...

4M ago

BDTX

Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

Wedbush raised the firm’s price target on Black Diamond Therapeutics (BDTX) to $14 from $13 and keeps an...

6M ago

BDTX

Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)

“We continue to focus on advancing silevertinib for the treatment of patients with EGFRm NSCLC and EGFR altered...

6M ago

BDTX

BDTX Upcoming Earnings Report: What to Expect?

Black Diamond Therapeutics, Inc. (BDTX) is scheduled to report 4th quarter earnings on 03/18/2026. Regarding Q4 estimates, Wall...

6M ago

BDTX

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $8 from...

8M ago

BDTX

Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer

Black Diamond Therapeutics, Inc. ($BDTX) announced an update on their ongoing clinical study. Study Overview Black Diamond Therapeutics...

8M ago

BDTX

3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026

Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy”...

9M ago

BDTX

BTBT

BDTX FAQ

What was Black Diamond Therapeutics’s price range in the past 12 months?

Black Diamond Therapeutics lowest stock price was $1.60 and its highest was $4.94 in the past 12 months.

What is Black Diamond Therapeutics’s market cap?

Black Diamond Therapeutics’s market cap is $121.80M.

When is Black Diamond Therapeutics’s upcoming earnings report date?

Black Diamond Therapeutics’s upcoming earnings report date is Nov 09, 2026 which is in 61 days.

How were Black Diamond Therapeutics’s earnings last quarter?

Black Diamond Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.

Is Black Diamond Therapeutics overvalued?

According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Black Diamond Therapeutics pay dividends?

Black Diamond Therapeutics does not currently pay dividends.

What is Black Diamond Therapeutics’s EPS estimate?

Black Diamond Therapeutics’s EPS estimate is -0.09.

How many shares outstanding does Black Diamond Therapeutics have?

Black Diamond Therapeutics has 57,453,747 shares outstanding.

What happened to Black Diamond Therapeutics’s price movement after its last earnings report?

Black Diamond Therapeutics reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 7.263%.

Which hedge fund is a major shareholder of Black Diamond Therapeutics?

Currently, no hedge funds are holding shares in BDTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Black Diamond Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-24.86%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Black Diamond Therapeutics (BDTX) Earnings & Revenues

Historic Earnings Reports

BDTX Stock 12 Month Forecast

Average Price Target

$10.33

▲(361.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","15":"$15","3.75":"$3.75","7.5":"$7.5","11.25":"$11.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.333333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.75,7.5,11.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.96,3.88,4.800000000000001,5.720000000000001,6.640000000000001,7.5600000000000005,8.48,9.4,10.32,11.240000000000002,12.16,13.080000000000002,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.677948717948718,3.315897435897436,3.9538461538461536,4.591794871794871,5.22974358974359,5.867692307692307,6.505641025641025,7.143589743589743,7.781538461538461,8.419487179487179,9.057435897435898,9.695384615384615,{"y":10.333333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.04,2.4984615384615383,2.956923076923077,3.4153846153846157,3.873846153846154,4.332307692307692,4.7907692307692304,5.24923076923077,5.707692307692308,6.166153846153846,6.624615384615384,7.0830769230769235,7.541538461538462,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.8,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.69,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >